Crohn's Disease Drug Landscape 2026

Crohn's disease is a chronic autoimmune condition and one of two major forms of inflammatory bowel disease (IBD), alongside ulcerative colitis (UC). Affecting over 500,000 Americans, Crohn's can cause inflammation anywhere in the GI tract but most often affects the small intestine. The inflammation penetrates deep through all layers of the bowel wall and typically occurs in scattered patches separated by normal tissue. Treatment has evolved dramatically from corticosteroids to targeted biologics and small molecules. The landscape is now dominated by TNF inhibitors, IL-23 blockers, integrin antagonists, and JAK inhibitors, with emerging targets like TL1A showing promise. Many therapies are approved for both Crohn's and UC, making the IBD market highly interconnected.

Current Crohn's disease treatments target several key inflammatory pathways. TNF inhibitors like Remicade and Humira remain widely used, while newer IL-23 blockers and JAK inhibitors offer alternatives for patients who don't respond to anti-TNF therapy.

Note: Counts include originator drugs only. Biosimilars are tracked separately.

Patent and exclusivity expirations for Crohn's disease biologics. Humira lost exclusivity in 2023, opening the market to multiple biosimilars. Stelara and Entyvio face upcoming patent cliffs, creating opportunities for biosimilar competition and potential cost savings.